All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-06-26T12:02:00.000Z

Guidance for management strategies in early myelofibrosis

Jun 26, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

Bookmark this article


A summary of best practice recommendations for the management of patients with early myelofibrosis (MF) has been published in Current Hematologic Malignancy Reports by Bose.1 Guidance for early diagnosis, risk satification, and symptom management were summarized.


Key learnings1

Risk stratification tools, including the Dynamic International Prognostic Scoring System (DIPSS) and Mutation-Enhanced International Prognostic Scoring System (MIPSS)70 are recommended to determine accurate risk status in early MF.

Molecular testing for mutations and adverse prognostic markers is recommended during the initial workup to help tailor the treatment plan to the patient’s specific genetic profile.

Early initiation of treatment is crucial in both patients with intermediate-2 risk or higher, as well as patients who are symptomatic with lower risk.

Data support the early use of ruxolitinib in higher-risk patients, to improve overall survival and symptom burden.

Active treatment for significant symptoms, such as fatigue and splenomegaly, is recommended regardless of risk status.

These findings highlight the importance of active treatment in managing early MF to improve survival and reduce symptom burden and disease progression.


  1. Bose P. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices. Curr Hematol Malig Rep. 2024;19(3):111-119. DOI: 1007/s11899-024-00729-8.

HCPs, what is your preferred format for educational content on the MPN Hub?

Publication summaries

50%

Visual abstracts

25%

Expert videos

15%

Expert podcasts

10%

20 votes

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox